MedTrace Logo

Selective Estrogen Modulation and Melatonin in Early COVID-19

NCT04531748 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-05-10

No results posted yet for this study

Summary

This study is a randomized, double-blind, controlled clinical trial to evaluate the effects of toremifene and/or melatonin in adults with mild COVID-19.

Conditions

  • Covid19

Interventions

DRUG

Toremifene

Participants will be instructed to take 60mg of oral toremifene capsule daily, 30 minutes before bedtime.

DRUG

Melatonin

Participants will be instructed to take the pills orally around the same time in the morning and 30 minutes prior to bedtime in the evening.

OTHER

Placebo

Oral placebo will be used with the same number and appearance to the pills as the interventions.

Sponsors & Collaborators

  • Reena Mehra, MD

    lead OTHER

Principal Investigators

  • Reena Mehra, MD · The Cleveland Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-31
Primary Completion
2022-09-30
Completion
2022-09-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04531748 on ClinicalTrials.gov